PRESENTATION

FY2026 — Results presentation

FY2026PDF · 62 pages3.3 MB
1
Audited Results
for the year ended
30 June 2026

-- 1 of 62 --

2
Performance overview
Normalised
profit
+17%
to R17 750m
Headline
earnings
+34%
to R12 923m
Normalised
headline earnings
+21%
to R11 795m
New
business
+6%
to R28 155m
Non-insurance
income
+10%
to R7 282m

-- 2 of 62 --

3
Group strategy overview
Financial
framework
Trends Business
model
Business
composites
1 2 3 4 5
Purpose,
Ambition and
context

-- 3 of 62 --

4
FY2026 | 2 years into our 5-year strategy (2025-2029)
1
2
3
Increasing the efficacy and
repeatability of the Vitality Shared-
value Model, globalising and
translating it into definable,
measurable impact
Unique high-growth, strong cash-
generative model delivering superior
RoE without recourse to additional
capital, while concurrently building
platforms for future growth
Two composites – Discovery SA and
Vitality – defined by unique value
propositions, competitive advantage
and customer impact
Business
model
Financial
framework
Business
strategy
𝑒𝑥
𝑠𝑥
𝛼	SHAREHOLDERS
CUSTOMERS
SOCIETY

-- 4 of 62 --

5
Financial framework
Strategic choices
Normalised
profit growth
Cash conversion
ratio Normalised RoE
Leverage
% spend on new
Dividend cover
15-20%
CAGR
FY25-FY29 60-70%	FY25-FY29 15-20%
FY25-FY29 ≤5x
FY25-FY29
c5%FY25-FY29
10-20% FY25-FY29

-- 5 of 62 --

6
Resilient to changing macroeconomic conditions
1 Rates are derived as the single constant discount rate that gives the same PV as discounting our projected cash flows using the curves; 2 DSY Life and VitalityLife Store of value (CSM+RA) pre-tax, net of Insurance finance reserve (IFR)
SA single equivalent rates derived
from valuation curves1
Falling SA interest rates
enhanced value metrics
Exchange rates indexed to July 2023
Currency translation headwinds from
Rand appreciation and Yen weakness
Indices indexed to July 2023
Strong market performance
drove investment gains
0
0.5
1
1.5
2
2.5
Jul-23	
Sep-23	
Nov-23	
Jan-24	
Mar-24	
May-24
Jul-24	
Sep-24	
Nov-24	
Jan-25	
Mar-25	
May-25
Jul-25	
Sep-25	
Nov-25	
Jan-26	
Mar-26	
May-26
CSI 300 STAR 50 (tech stocks)
S&P 500 JSE all share
0.85
0.9
0.95
1
1.05
1.1
1.15
Jul-23	
Sep-23	
Nov-23	
Jan-24	
Mar-24	
May-24
Jul-24	
Sep-24	
Nov-24	
Jan-25	
Mar-25	
May-25
Jul-25	
Sep-25	
Nov-25	
Jan-26	
Mar-26	
May-26
YEN/USD ZAR/USD
ZAR/GBP ZAR/RMB
FY24 FY25 FY26 FY24 FY25 FY26
-
2
4
6
8
10
12
14
16
Jun-23	
Sep-23	
Dec-23	
Mar-24	
Jun-24	
Sep-24	
Dec-24	
Mar-25	
Jun-25	
Sep-25	
Dec-25	
Mar-26	
Jun-26
Nominal Real CPI
FY24 FY25 FY26
2%
4%
Reduction in earnings
Reduction in Embedded Value
37%
13%
5%
Increase in store of value2 (IFRS 17)
Increase in Group Net Equity (IFRS 17)
Uplift in Embedded Value
22%
42%
Increase in average Invest AUM
Increase in PAHI investment
income and gains
Impact on FY26 results

-- 6 of 62 --

7
Strong operating profit growth
Health 4 629 +9%
Life 5 872 +6%
Invest 2 157 +9%
Insure 1 013 +24%
Bank 370 >600%
Other SA1 -173 -66%
Discovery SA 13 868 +16%
VitalityHealth 1 896 +60%
VitalityLife 782 +23%
Ping An Health Insurance 1 317 +9%
Vitality Global Markets2 186 -29%
Vitality AI3 -299 >+200%
Vitality 3 882 +21%
Normalised profit, ZARm
1 Includes Discovery Vitality; 2 Vitality Network and VHI-Other; 3 Includes Other Vitality central costs
FY01	
FY02	
FY03	
FY04	
FY05	
FY06	
FY07	
FY08	
FY09	
FY10	
FY11
FY12	
FY13	
FY14	
FY15	
FY16	
FY17	
FY18	
FY19	
FY20	
FY21	
FY22	
FY23	
FY24	
FY25	
FY26
to R17 750m
+17%
Normalised operating profit
IFRS 17	
IFRS 4

-- 7 of 62 --

8
New business and non-insurance income over time
to R28 155m
+6%
New business
FY01	
FY03	
FY05	
FY07	
FY09	
FY11
FY13	
FY15	
FY17	
FY19	
FY21	
FY23	
FY25
Sasolmed
FY22 FY23 FY24 FY25 FY26
Bank
+31%
FY22 FY23 FY24 FY25 FY26
Vitality
UK
+14%
FY22 FY23 FY24 FY25 FY26
PAHI
(own
licence)
-6%
FY22 FY23 FY24 FY25 FY26
SA
+8%
FY22* FY23 FY24 FY25 FY26
Vitality
Global
Markets
-10%
*FY22 normalised by including Solutions Revenue, which was included from FY23 onwards
FY22 FY23 FY24 FY25 FY26
Health
+30%
+10%
Non-insurance income
to R7 282m
FY22*
FY23
FY24
FY25
FY26
Health
Life
Invest
Insure
New closed
schemes &
other
ZAR
GBP
RMB
ZAR
ZAR
USD

-- 8 of 62 --

9
Robust growth in Group Embedded Value from strong
operational performance
10,947
3,301
6,307 4,803
Opening EV
2,821
VNB RDR unwind
2,139
Non-
economic
variances &
assumption
changes
Profit from
non-covered
businesses
Operational
EV
Economic
variances &
assumption
changes
Forex
2,385
Finance
costs,
investment
income &
other
482
1DP lease
termination
1,475
Change in
capital &
dividends
Closing EV
14.1%
Return on EV
R126 554m
R145 762m R142 924m
+31%
on FY25
+33%
on FY25
+30%
on FY25
+2.2%
Contribution
to RoEV: +8.7% +1.7% +2.6% +5.0% -3.8% -1.9% -0.4% = 14.1%	
NA	= 15.2%

-- 9 of 62 --

10
Exceptional cash growth driven by strong operating
performance
Cash
generated
from in-force
7.3
2.8
New business
& tax
Operating
cashflow
2.2
1.6
Servicing costs
1.2
Investment
in growth
1.4
2.1
Finance
repayments
0.8
Once-offs
(CMT)
Net cash flow
21.4
11.3
3.6
New
business
Tax
Dividends
Finance costs Financing &
matching
Repayment
of debt*
FY26 (Rbn)
85%
cash
conversion
ratio
Cash generation Cash spend
5.3
6.3
9.0
11.3
FY23 FY24 FY25 FY26
Operating cashflow (Rbn)
+26%
to R11.3bn
*Excl debt raised for 1DP transaction. 1 DP transaction (debt raised and purchase price) is shareholder cash flow neutral

-- 10 of 62 --

11
0%
20%
40%
60%
80%
100%
FY22 FY23 FY24 FY25 FY26
Group maintains a position of considerable financial
strength and flexibility
Strong cash conversion Well capitalised FLR decreasing
Group cash conversion ratio Financial leverage ratio	Solvency cover
DHMS solvency
(unaudited)
Jun 25
Cover
Jun 26
Cover
Life 1.9x 1.7x
Insure 2.1x 2.1x
VH 1.8x 1.9x
VL 2.0x 1.9x
Bank1 1.2x 1.1x
PAHI2 3.3x 2.9x
31.7%
85%
31.3%
1 Capital Adequacy Ratio; 2 Comprehensive Solvency Ratio, definition set by China Banking and Insurance Regulatory Commission
0%
5%
10%
15%
20%
25%
FY22 FY23 FY24 FY25 FY26
15.4%
12.8%
(excl 1DP debt)

-- 11 of 62 --

12
Supportive below-the-line performance
Final dividend declared
273 cps
36% growth
Full-year dividend
384 cps
33% growth
4.5x dividend cover
R million
Actual Actual %
2026 2025
Normalised profit from operations 17 750 15 210 17%
FY2026 once-off: 1DP lease termination gain 1 463 -
FY2026 once-off: Disposal / dilution gains (losses) from equity accounted investments 211 -32
Finance charges excl. 1DP finance lease -1 525 -1 810
1DP finance lease impact -33 -72
Investment income and fair value gains on financial instruments 515 457
Forex (losses)/gains, net of CCBS 1 -36
Other -116 -222
Segmental total: Profit before tax 18 266 13 495 35%
Segmental total: Income tax expense -5 048 -3 937
Profit after tax 13 218 9 558 38%
Profit not attributable to ordinary shareholders -221 -231
Profit or loss on disposal/dilution gains from equity accounted investments -222 25
Impairment - HFS assets change of intention net of tax - 79
Impairments and derecognition losses 148 194
Headline earnings 12 923 9 625 34%
FY2026 once-off: Lease termination gain -1 068 -
Amortisation of intangibles from business combinations 94 104
DTA recognised on prior period losses -205 -
Other normalised headline earnings adjustments 51 52
Normalised headline earnings 11 795 9 781 21%

-- 12 of 62 --

13
FY29 Ambition remains intact
-
5,000
10,000
15,000
20,000
25,000
30,000
FY01	
FY02	
FY03	
FY04	
FY05	
FY06	
FY07	
FY08	
FY09	
FY10	
FY11	
FY12	
FY13	
FY14	
FY15	
FY16	
FY17	
FY18	
FY19	
FY20	
FY21	
FY22	
FY23	
FY24	
FY25	
FY26
FY29
Operating profit corridor
(Applying CAGR target to FY24 profit)
15%
20%
Ahead of FY29 Ambition run rate
Operating profit Rm
Capital allocation intact
FY25-FY29
Strategic
choices
Normalised
profit growth
Cash
conversion
ratio
Normalised
RoE
Leverage
% spend on
new
Dividend
cover
15-20%
CAGR
60-70% 15-20%
≤5x
c5%
10-20%
Targets FY25 FY26
Profit
CAGR 15-20% 29% 17%
Cash
conversion
ratio
60-70% 80% 85%
Spend on
new c5% 3% 2%1
FLR 10-20% 16.8% 12.8%2
15.4%
Dividend
cover ≤5x 5x 4.5x
RoE 15-20% 15.4% 16.5%
1 Spend on new includes Vitality AI, VHI Other and Discovery Green; 2 excluding 1DP debt. Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame
After the strong performance in the first two years of this period, the Group now expects to achieve
compound growth in the middle to upper end of this ambition over the 5-year period

-- 13 of 62 --

14
Business model
𝑒𝑥
𝑠𝑥
𝛼SHAREHOLDERS
CUSTOMERS
SOCIETY

-- 14 of 62 --

15
Under 1
5-9
15-19
25-29	
35-39	
45-49	
55-59	
65-69	
75-79
85+
0%
5%
10%
15%
20%
25%
30%
35%
40%
2025 2030 2035 2040
Powerful demographic and economic forces are driving
healthcare costs higher
Proportion aged 65+
Ageing populations
65+ per 100 working-age
population
Rising old-age
dependency ratio
Healthcare costs by age
group
Healthcare costs
rise steeply with age
Healthcare costs raise
faster than CPI
Baumol’s cost disease
-100%
-50%
0%
50%
100%
150%
200%
250%
1998 2008 2018
Hospital
services
College tuition &
fees
Child care &
nursery school
Medical care
services
Average hourly
earnings
Food &
beverages
CPI for all
items
New cars
Apparel
Wireless
telephone
services
Toys
Televisions
3.4x higher healthcare
costs for 65+
+13%-25%
by 2030
Implied long-term healthcare cost increase per taxpayer
+30%-57%
by 2035
+49%-98%
by 2040
Behaviour change has
a causal impact on
health and mortality
Relative mortality for
the 45-65 age group
Relative mortality for
the 65+ age group
Relative reduction for
the 45-65 age group
Relative reduction for
the 65+ age group
Mortality
Healthcare costs
0 Low MediumHigh
-36% -38%
-58%
0 Low MediumHigh
-29%
-52%
-59%
No
habit
Strong
poor
Strong
good
-14%
-29%
No
habit
Strong
poor
Strong
good
-16%
-25%
-
20
40
60
80
2025 2030 2035 2040
World Bank data

-- 15 of 62 --

16
Shared value creates a reinforcing cycle of value for the
shareholders, customers and society
𝛼 = 𝑓( )Shareholders
Excess returns to shareholders
through the dynamics of the
model
𝑒𝑥= 𝑓( )Customers
Longer lifespans and
healthspans driven by
engagement in the model
𝑠𝑥 = 𝑓(Σ )Society
Positive societal impact arising
from the cumulative
improvements in customers’
health and longevity

-- 16 of 62 --

17
Excess returns to shareholders through the dynamics
of the model
1 2026 contribution differential between Discovery Health Medical Scheme and the next seven competitors;
9.2%
Operating
margin
14.8%
Operating
margin
RF+9.5%
New business
IRR
RF+6.6%
New business
IRR
Cost-to-income
77%
𝛼F𝑌26
Cost per
benefit unit1
-17.7%	6.2%
Operating
margin
11.9%
Operating
margin
RF+6.1%
New business
IRR
RF+9.7%
New business
IRR
Cost-to-income
91%
𝛼F𝑌25
To be disclosed at
upcoming disclosure of
contribution increases
𝛼

-- 17 of 62 --

18
R1 000m
EV mortality & morbidity
experience variance
Longer lifespans and healthspans driven by
engagement in the model
𝑒𝑥
1 2026 contribution differential between Discovery Health Medical Scheme and the next seven competitors
R483m
Value of
claims savings
-17.7%
Cost per
benefit unit1
2.7%
Credit loss
ratio
R151m
EV mortality & morbidity
experience variance
R530m
EV mortality & morbidity
experience variance
R2.2bn
Total FY26
claims savings
Mortality AvE
None Blue Bronze &
Silver
Gold &
Diamond
Expected FY26
Mortality AvE
Bronze Silver Gold Platinum
Expected FY26
In-hospital claims
Bronze Silver Gold Platinum
Loss ratio
Bronze Silver Gold Diamond	Blue
In-hospital claims
Blue Bronze Silver Gold &
Diamond
Credit loss ratio
Blue Bronze Silver Gold &
Diamond

-- 18 of 62 --

19
Positive societal impact arising from the cumulative
improvements in customers’ health and longevity
All figures for FY2026. 1 Dependent on market dynamics and regulations; 2 Restated to incorporate latest changes
𝑠𝑥
Increase in lives
impacted globally
Increase in healthy
activities
Increase in life years
saved globally
Change in lives
impacted (m)
Change in healthy
activities (m)
Change in life years
saved (m)
FY26 life years saved	Lives impacted FY26 healthy activities
725m c5.2m years	c54m
503
576 640
725
FY23 FY24 FY25 FY26
35
42
49
54
FY23 FY24 FY25 FY26
+11% +13%
3
3.7
5 5.2
FY23 FY24 FY25 FY26
+4%
13.7 14.9 16.5 17.2
FY23 FY24 FY25 FY26
FY26 shared-value
dividend
Change in shared-
value dividend
Value returned to clients
R17.2bn
+4%
Lower cost of insurance1
10 – 25%
Life
5 – 20%
Health
2

-- 19 of 62 --

20
New data dimensions are continuously strengthening our
understanding of behaviour, health and risk
VAR Go-Live Date = 19th Sept 2015, PHP Go-Live Date = 1st Jan 2025, Sleep Go-Live Date = 1st May 2026
Vitality Sleep Rewards
1 3 5 7 9 11 13 15 17 19 21 23 25 27
Days since go live
Vitality
Sleep
Rewards
Personal
Health
Pathways
Vitality
Active
Rewards
Cumulative activations for various
Vitality benefits
16%
Members
improved
sleep habits
7%
In-hospital claims
improvement for
those shifting habits
24%
Reduction in mortality
for improved sleep
duration & regularity

-- 20 of 62 --

21
Business strategy
+16% +21%
FY26 profit growth:
Super Bank strategy Vitality AI

-- 21 of 62 --

22
Discovery SA
Strategic focus areas
Discovery Bank – Scale,
functionality, leadership
The Super Bank strategy –
Integrated Discovery ecosystem
Discovery SA businesses – Every
business #1
1
2
3
12.5% to 17.5%
average earnings
growth p.a.
(FY25-FY29)
16%
FY26

-- 22 of 62 --

23
+26% +17% +>600%	+31%
to 1.6m to R27.2bn to R370m	to R3.1bn
+40%
to R12.9bn
Total
accounts
Total
clients
+26%
to 3.8m
2022 202320242025 2026
Accounts Clients
2022 202320242025 2026 2022 202320242025 2026
NII NIR
2022 202320242025 2026
Discovery Bank
Gross retail
advances1
Revenue2
(NII+NIR) Profit	Deposits
1 HL: Home loans, PL: Personal loans, CC: Credit Card, SCF: Standard Credit Facility, RCF: Revolving Credit Facility; 2 NII includes the allocation of interest earned on Treasury Bills (recognised at fair value gains in the income statement)
2022 2023 2024 2025 2026
SCF and CC
PL and RCF
HL

-- 23 of 62 --

24
Disciplined growth and AI-enabled efficiency driving quality
scale
Daily sales Credit loss ratio2	Home loan quality1
0
200
400
600
800
1 000
1 200
1 400
1 600
Jun-22	
Oct-22	
Feb-23	
Jun-23	
Oct-23	
Feb-24	
Jun-24	
Oct-24	
Feb-25	
Jun-25	
Oct-25	
Feb-26	
Jun-26
Discovery Bank
Bank A	
Bank B	
Bank C	
Bank D
Non-Bank E
Other
Super prime: <5%
Prime plus: 5%-<7%
Prime: 7%-<11%
Near prime: 11%-<16%
Subprime: 16%+
1 TransUnion Report, View 11: Market Share of new bookings in Mortgage Bond Industry, including banks A to E, other banks, and other non-banks. Q1 2026; 2 Unsecured credit loss ratio excludes personal loans which were launched recently and do not yet have a comparable prior-year
history. Market CLR has been adjusted for Discovery’s advances mix, excluding Personal Loans (PL). 2026 market data reflects the latest available information as at December 2025, pending publication of 2026 financial statements
Average sales per workday
(calendar month)
Risk split based on HLs
issued`
0%
1%
2%
3%
4%
5%
6%
7%
2022 202320242025 2026
Secured
Unsecured
Market (Unsecured)
Overall
Servicing
distribution
Call centre
efficiency
85%
95%
105%
115%
125%
135%
145%
Jan-25	
Mar-25	
May-25
Jul-25
Sept-25	
Nov-25	
Jan-26	
Mar-26	
May-26
Total calls
Total clients
Total calls vs clients
baselined to Jan-25
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Jan-25	
Mar-25	
May-25
Jul-25
Sept-25	
Nov-25	
Jan-26	
Mar-26	
May-26
Voice Call
In App Call
Chats
Discovery AI
GROWTH QUALITY EFFICIENCY

-- 24 of 62 --

25
Scalability gains driving operational margin expansion
Profitability	Client growth Revenue pc Expenses pc Impairments pc
1.57
2022 2023 2024 2025 2026
66 79 78 76 77
97
105 119 120 122
2022 2023 2024 2025 2026
NII pcpm NIR pcpm
322
239
189
151
131
2022 2023 2024 2025 2026
16
19
16
19 18
2022 2023 2024 2025 2026
Clients (m) Revenue pcpm (R)
(excl. NBAC)
Expenses pcpm (R)
(excl. NBAC)
Impairments pcpm (R) Profit before NBAC
(Rbn)
-0.785
-0.499
-0.052
0.368
0.865
-1.3
-0.8
-0.3
0.3
0.8
1.3
1.8
2.3
2.8
3.3
2022
2023
2024
2025
2026
2027
2028
2029
Actuals Low
Medium High
× =	−	−	ሼ ሽ

-- 25 of 62 --

26
Exceptional client experience continues to differentiate
Discovery Bank
NPS = % promoters (9–10) minus % detractors (0–6)
Competitor
B
57%
25%
18%
40
Competitor
E
54%
24%
22%
31	62%
20%
18%
44
Competitor
D
63%
23%
14%
49
Competitor
C
Competitor
A
60%
19%
21%
40
Competitor
F
Discovery
Bank
71%
17%
59
12%
70%
18%
59
12%
73%
14%
60
13%
Competitor
G Competitor
B
74%
13%
62
Competitor
E
77%
14%
69
Competitor
D
74%
20%
69
Competitor
C
Competitor
A
67%
24%
58
Competitor
F
Discovery
Bank
78%
13%
69
84%
78
86%
81
Detractors (0–6) Passives (7–8) Promoters (9–10)
BANKING PRIVATE BANKING
Ask Africa Orange
Index Ranking
#2
Ask Africa Orange
Index Ranking
#1
Net Promoter Score (NPS) Net Promoter Score (NPS)

-- 26 of 62 --

27
Rationale for the Super Bank strategy
Faster integration2
Average time to take up additional
Discovery products (years)
0.0
0.5
1.0
1.5
2.0
2.5
Second product
Third product
Fourth product
Fith product
Bank Non Bank
Integration opportunity
1 Discovery products included - Insure, Invest, Health, Life, Gap and Vitality; 2 Non-Bank includes Discovery Health, Life, Invest and Insure
Expanding reach1
New business by number of
existing Discovery products
56%
70%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2022 2023 2024 2025 2026
0 1 2 3 4+
2026
>6m lives
Discovery Health
Medical Scheme
Discovery
Bank
Discovery
Invest
Discovery
Insure
Discovery
Life

-- 27 of 62 --

28
The Super Bank strategy – all components are aligned

-- 28 of 62 --

29
The Super Bank strategy – unlocking exponential value
across the ecosystem
Portfolio value	Functionality
EXPONENTIAL SHARED
VALUE
MANAGEMENT,
FUNCTIONALITY AND ACCESS
Product houses
FORMING THE RAILS OF
THE GROUP
Payment
Security
Service
Rewards
Ecosystems
An integrative control layer for a customer's entire economic life – orchestrating their financial, health, and
lifestyle ecosystems, and converting verified behaviour change into a single currency of real value
VITALITY
HEALTH
VITALITY
MONEY
VITALITY
DRIVE
Ecosystem Product Behaviour

-- 29 of 62 --

30
Discovery Health
Figures are excluding Healthy Company in prior periods
New business Membership Non-Scheme lives
+9% +10% +22%	3.91m
to R4 629m to R10 495m to 330k lives	Lives under
administration
2022 2023 2024 2025 2026 2022 2023 2024 2025 2026
1993	
1996	
1999	
2002	
2005	
2008
2011
2014	
2017	
2020	
2023	
2026
Non Scheme Products
Restricted Schemes
DHMS
Normalised profit
Nov-18	
Jun-19	
Jan-20	
Aug-20	
Mar-21	
Oct-21	
May-22	
Dec-22
Jul-23
Feb-24	
Sep-24	
Apr-25	
Nov-25	
Jun-26
Flexicare
Gap cover
AHI

-- 30 of 62 --

31
Personal Health Pathways addresses the increasing disease
burden in DHMS
Cancer prevalence
increasing
Oncology prevalence
increasing over time
18% of members living with
2+ chronic conditions
2015	
2016	
2017	
2018	
2019	
2020	
2021	
2022	
2023	
2024	
2025
+120%
0%
5%
10%
15%
20%
25%
30%
35%
2015
2017
2019
2021
2023
2025
%
members
% total
claim costs
10%
8%
15%
14%
16%
3+
conditions
2
conditions
1
condition
43%
of total
claims
costs
Growing chronic
disease burden
Mortality improvement
over past 10 yrs	5.6%
1.6x
>15% Lower severe diagnosis
rate for PHP vs non-PHP
members (diabetes and
mammograms)
+7yrs
Improved life expectancy
for members living with
cancer over past 15 yrs
Better survival for early-
stage cancer diagnosis
Strong growth ensures
sustainability
Gross new business
1 Effective contribution differential between DHMS and the next seven competitors; Effective contribution differential and increases take into account contribution deferrals
0
50,000
100,000
150,000
200,000
250,000
300,000
350,000
2024 2025 2026
14.7% higher health risk, 17.7% lower cost per unit benefit1
𝜶 Delivering demonstrable alpha
46%
higher cancer
patient prevalence
than rest of industry

-- 31 of 62 --

32
Sustained growth and financial strength for Discovery Health
Medical Scheme (DHMS)
Membership Customer satisfaction Solvency
DHMS Rest of the industry
Others
57.7% Market share
0%
5%
10%
15%
20%
25%
30%
35%
40%
0
5
10
15
20
25
30
35
2021-22 2023-24 2025-26
Reserve
Actual Solvency
Required Solvency
R33.2bn
31.3%
AAA
Projected unaudited
reserves
Projected unaudited
solvency
Credit rating
Low proportions of members change plans, with
more members upgrading than downgrading
Lapses continue to remain stable
0%
2%
4%
6%
8%
10%
2022 2023 2024 2025 2026
96% no plan changes
0%
1%
2%
3%
2022 2023 2024 2025 2026
Upgrades Downgrades
Membership and open market share as at June 2026	
Plan movements as at 1 January

-- 32 of 62 --

33
Discovery Life
Cash generation New business VNB
+6% 67% +114%	+1%
to R5 872m cash conversion to R241m	to R3 244m
Normalised profit
2022 2023 2024 2025 2026
IFRS 17
-722
1,464
2,193
3,327
3,888
2022 2023 2024 2025 2026
Cash flow before financing
initiatives and dividends to
Group (Rm)
+9%
Individual + Group
+43%
Individual Life
2025 2026	2022 2023 2024 2025 2026
+9%
New business in VNB
(Life + Group Life)
Servicing increases
Umbrella business Automatic increases
Leading market share
2.5x the average of the next 5 largest writers in
the underwritten retail risk business1
1. Market share source: NMG market report Q2 2026 (Jun 2026)
New business
APE (EV)

-- 33 of 62 --

34
Mortality and morbidity
Premium and fee income
Persistency
Policy alterations
Other
Total non-economic
Economic
Total
June 2025
New Business
Expected Unwind	
excl. new business
Experience	
Variances	
Economic	
Dividends
Other
December 2025
June 2025
Positive operating variances Improved VNB margin Growth in Embedded Value
Individual Life:
3.8%
(IRR: RF +6.8%)
Life (excl. Invest) VNB margin (%)
Individual Life:
4.7%
(IRR: RF + 7%)
22.8%Annualised RoEV1
12.3% excl. economic updates
Discovery Life Ltd EV variances (Rm) Discovery Life Ltd EV growth (Rm)
June 2026
Economic assumptions
52 164
-204
62 863
469
4 931
5 482
1 222
-1 200
Premium & fee income
Persistency
Other
Total non
-economic	
Economic
Total
Policy alterations
Mortality & morbidity
819
1 222
Strong operating experience and improved new business
economics driving EV growth
1 Before dividend payments
June 2025	
Economic
Business mix
Model changes
Other
December 2025
June 2025	
June 2026
Non
-economic	
variances
Business mix
Model changes
Economic
New initiatives & other
2.1%
3.8%

-- 34 of 62 --

35
None Blue Bronze Silver Gold Diamond
Impact of the model is more pronounced compared to prior years,
and increasingly valuable within an ageing book
Mortality AvE by engagement level
(indexed to blue Vitality status)
Positive mortality experience validating the impact of
the shared-value model
Mortality AvE by age
Strong engagement & shared-value impact
observed for members at older ages
100%
Long-term
expected
FY22	
FY26
Mortality experience for
members over the age of 50
< = 50 >50
100%
-8%
Exposure Share of
mortality gain
90%
Engaged
(Silver, Gold
& Diamond)
Unengaged
(None, Blue &
Bronze)
10%
35%
65%
of the existing Discovery Life
book are highly engaged
40%

-- 35 of 62 --

36
Reduction in yield curves supports IFRS 17 growth
ZARm
2,121
10,400
3,958
2,328
Store of value
June 2025: CSM
+ RA, net of IFR
New business Insurance
finance
income/expense
-905
Non-financial
risk variances &
basis changes
-2,649
Release to
earnings
Store of value
June 2026: CSM
+ RA, net of IFR
23,250 CSM = 23 507
RA = 7 877
IFR = -8 134
CSM = 24 391
RA = 11 133
IFR = 2 980
18,597
= 66%
Growth from June 2025
IFR
RA
CSM
38,504
SA Life (GMM) + SA Invest (GMM). Store of value is calculated net of reinsurance but gross of tax. CSM = Contractual Service Margin; RA = Risk Adjustment; IFR = Insurance Finance Reserve; OCI = Other Comprehensive Income; IFIE = Insurance Finance Income or Expense
CSM, RA and IFR increased over the period Components of Life segment earnings
(incl. Premium Allocation Approach (PAA) business such as
Group Life)
2 289
2 765
818 5 872
CSM & RA
release
IFIE Other Life
segment
earnings
Includes
claims
and NAV
variances

-- 36 of 62 --

37
Discovery Invest
Assets under
administration New business
+9% +15% +13%
to R2 157m to R205bn to R3 865m
Jan-18	
Jan-19	
Jan-20	
Jan-21	
Jan-22	
Jan-23	
Jan-24	
Jan-25	
Jan-26
2022 2023 2024 2025 2026
Guaranteed	API from guaranteed
+20%
Excl.
guaranteed
2022 2023 2024 2025 2026
One-offs	One-off items
+22%
Excl. one-
offs
IFRS 17
Normalised profit
2022 2023 2024 2025 2026
Net flows
+97%
to R6.3bn

-- 37 of 62 --

38
Discovery Insure
Insurance revenue Gross new business Operating margin
+24% +4% +23%	+2%
to R1 013m to R6 448m to 14.8%	to R1 390m
2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026
Normalised profit

-- 38 of 62 --

39
Vitality continues to drive improvement in quality
Disciplined new
business growth
Lapses improve by
status
Loss ratio improves
by status
Blue
Bronze
Silver
Gold
Diamond
75%
80%
85%
90%
95%
100%
2022
2023
2024
2025
2026
Average risk profile
Superior risk profile
Blue
Bronze
Silver
Gold
Diamond
Relative lapse rate by status	Relative loss ratio by status Loss ratio
Steady loss ratio despite
weather normalisation
0%
10%
20%
30%
40%
50%
60%
70%
2022 2023 2024 2025 2026
-30%
New business book based
on insurance risk exposure

-- 39 of 62 --

40
Super Bank strategy

-- 40 of 62 --

41
Strategic focus areas
Vitality UK – Centre of excellence
Vitality Global Markets – Scaling
the model through partnerships
and equity stakes
PAHI – Driving expansion through
products and distribution
1
2
3
Vitality
UK	
Global	
Markets
Health Insurance
20% to 30%
average earnings
growth p.a.
(FY25-FY29)
21%
FY26 Like-for-like
ZAR
26%

-- 41 of 62 --

42
Vitality UK

-- 42 of 62 --

43
Vitality UK
+52% +13% +6%	+14%
to £118.1m to £1.4bn to 2.08m	to £260.1m
2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026
IFRS 17
Normalised profit Earned premiums New business Lives covered

-- 43 of 62 --

44
VitalityHealth
Normalised profit Earned premiums New business Lives covered
+65% +12% +2%	+4%
to £83.6m to £909m to 1.08m	to £126.6m
2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026
IFRS 17

-- 44 of 62 --

45
Margin outperformance driven by strong premium growth and
experience, demonstrating strength of model
Relative growth in premiums
vs claims
(6-month average PLPM, rebased
to Jan 2023)
Premium levels remain
well matched to claims
Relative effect of Vitality status
on in-hospital claims spend1
(after normalising for other
claims factors)
Engagement driving
sizable health outcomes
Lapse rate (API) by Vitality
status
(relative to overall lapse rate)
Greater retention of
quality business
Operating margin relative to
7.5% guidance
Strong margin
11.7%
6.2%
2.8%
6.2%
9.2%
2022 2023 2024 2025 2026
7.5% margin guidance
0%
20%
40%
60%
80%
100%
120%
Bronze Silver Gold Platinum
Individual SME Overall
1 GLMs were used to adjust for key risk factors (e.g. age, location, product mix, duration, underwriting type, sales channel), isolating the relative impact of individual factors by holding others constant
95%
100%
105%
110%
115%
120%
125%
130%
Dec-22	
Mar-23	
Jun-23	
Sep-23	
Dec-23	
Mar-24	
Jun-24	
Sep-24	
Dec-24	
Mar-25	
Jun-25	
Sep-25	
Dec-25	
Mar-26	
Jun-26
100%
87%
79%
74%
Bronze Silver Gold Platinum
26%
Premium PLPM indexed to 2023
Claims PLPM indexed to 2023 (rolling 6m)

-- 45 of 62 --

46
VitalityLife
+27% +15% +11%	+25%
to £34.5m to £513.7m to 1.01m	to £133.5m
2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026 2022 2023 2024 2025 2026
IFRS 17
Normalised profit Earned premiums New business Lives covered

-- 46 of 62 --

47
Mortality experience by status
(Jul 22 – Jun 26, plans with
Optimiser, indexed to Bronze)
100%
84%
68%
51%
Bronze Silver Gold Platinum
Significant new business value and margin growth enabled by
Shared-value Insurance Model
VitalityLife new business market
share1
Strong growth in market
share & distribution
Engagement driving
mortality improvements
Drivers of new business value
Sales growth &
efficiencies driving value
Net value over time (£m)2
Sustained growth in new
business APE & net value
H1
FY24
H2
FY24
H1
FY25
H2
FY25
H1
FY26
H2
FY26
Sales
Underlying Profitability
Per policy initial expenses
+102%
+4%
-22%
100%
16
47
78
FY24 FY25 FY26
1 Gen Re Protection Pulse. FY26 data based on July 25 – July 26; 2 CSM & RA on NB excludes the impact of new reinsurance contracts attaching to the in-force book in the period.
Up 77% in 3 years
Advisers writing:
49%
7.4%
8.4%
10.4% 10.9%
13.5%
15.5%
FY21 FY22 FY23 FY24 FY25 FY26
+67%
Key competitors:

-- 47 of 62 --

48
Strong new business momentum supports growth under IFRS 17
CSM, RA and IFR increased over the period
Store of value is calculated net of reinsurance but gross of tax. CSM = Contractual Service Margin; RA = Risk Adjustment; IFR = Insurance Finance Reserve; OCI = Other Comprehensive Income; IFIE = Insurance Finance Income or Expense
GBPm
= 11%
Growth from June 2025
OCI
CSM+RA
Store of value
June 2025: CSM
+ RA, net of IFR
67,6
New business
13,1	9,3
Insurance
finance
income/expense
14,1
Non-financial
risk variances,
basis changes
& other
-43,3
Release to
earnings
Store of value
June 2026: CSM
+ RA, net of IFR
552.2
612.9

-- 48 of 62 --

49
Vitality Global
Markets
VN VHI

-- 49 of 62 --

50
2022 2023 2024 2025 2026	2022 2023 2024 2025 2026
Vitality Global Markets
Profit
Integrated API by
insurance partners	Revenue Lives
-24% +10% +16%	-10%
to $11m to $2.2bn to 9.78m	to $146m
2022 2023 2024 2025 2026	2022 2023 2024 2025 2026
VN SLI revaluation gains
VN SLI revaluation losses
+115%
accounting
for SLI
impacts
+115% to $23m
excl. SLI impact

-- 50 of 62 --

51
Delivering on the strategic priorities that position the
business for growth and scale
EUR = Europe, ME = Middle East, NA = North America
• Vitality AI, built with Google, launched in London (November 2025), with US launch to follow in September 2026
• Introduced a panel of shared-value reinsurance partners and several new Vitality Programme partners,
broadening the capability set available to partners
Deepening the
proposition
through Vitality AI
1
• Rebased SLI economics, with a joint commitment to 5m lives by 2030
• Investing alongside AIA to accelerate Shared-value Insurance in key markets
• Mutually terminated partnerships where strategic direction diverged, creating opportunities to pursue
optimal long-term partnerships in these markets
• Expanded Amplify Health with AI-enabled solutions and multi-year value-share economics in four key
markets, alongside a three-year partnership with Star Health, India's largest standalone health insurer
Focusing and
scaling existing
partnerships
2
• Building an active pipeline of potential carriers in Europe to establish optimal, long-term partnerships
• Prioritising growth in the US with John Hancock
• Expanding into health and public sector opportunities in Middle East
Pursuing growth
opportunities in
EUR, ME and NA
3
• Acquired WellSpark (Nov 24), Ramp Health (Mar 26) and Icario (Sep 26), adding coaching, condition
management, onsite clinical reach and member activation, and expanding to government sponsored health
plans
• Continuing to deploy technology-enabled engagement solutions, including Vitality AI, and expanding the
VHUS health plan footprint to 10 clients
• Finalised a partnership with HealthEquity, extending Vitality's reach to 10m+ HSA account holders
Accelerating US
growth through
organic expansion
and acquisitions
4

-- 51 of 62 --

52
Vitality AI | Google – one intelligent platform powering
the future of life and health insurance globally
1. Dependent on market dynamics and regulations

-- 52 of 62 --

53
Strong partner growth, with healthy pipeline supporting
future expansion
+10%
2024 2025 2026 2024 2025 2026	2024 2025 2026 2024 2025 2026 2024 2025 2026
Health US
-3% drop in average
YEN:USD 2025-2026
Integrated API ($m)
+17% -10% +16% +22%
Integrated
insurance
premium1 (¥m)
Integrated API
($m)
Lives Revenue ($m)
15
Opportunities
under
investigation
4
Opportunities in
active
negotiations
2
Opportunities in
contract
finalisation
VN VHI
1 Integrated Insurance Premium represents the cumulative in-force members annualised net premium; 2 Amplify Health’s reported revenue
Scaling existing partnerships Pursuing new
opportunities
2024 2025 2026
+27%
Revenue2 ($m)

-- 53 of 62 --

54
A differentiated proposition addressing a large and
growing US market
Capability expansion Addressable market Scale
c$5bn
c$130bn
Today
Integrated
health solution
Historically
Lifestyle risk
reduction only
Care navigation &
advocacy
c$24bn
Coaching & disease
management
c$90bn
Regulatory requirements
c$11bn
Lifestyle risk reduction c$5bn Lifestyle risk reduction c$5bn
Coaching depth | Nov-24
Individual and group coaching, disease
prevention and management, acquired
from EmblemHealth
Onsite clinical reach | Mar-26
Onsite and virtual clinical services,
occupational health, workers'
compensation risk mitigation
Government plan expertise and assets | Q1 FY27
Omnichannel outreach, health risk
assessments, gaps in care, custom surveys
PHYSICAL
ACTIVITY & SLEEP
CLINICAL
ACTIONS
EARLY DETECTION
& SCREENING
V I T A L I T Y	
H E A L T H	
C H E C K
P C P	
V I S I T
DISEASE
MANAGEMENT
O N C O L O G Y
D I A B E T E S C A R E
C A R D I O C A R E
M E N T A L H E A L T H
K I D N E Y C A R E
H I V C A R E
V A C C I N A T I O N S
M E D I C I N E	
A D H E R E N C E
C L I N I C A L	
C O A C H I N G	
C A N C E R	
S C R E E N I N G
BREAST	
CERVICAL	
PROSTATE	
COLORECTAL
G E N E T I C T E S T I N G
D E N T A L	
C H E C K - U P
E Y E T E S T
CHOLESTEROL	
BLOOD PRESSURE	
BLOOD GLUCOSE	
WEIGHT/BMI
M E N T A L R I S K	
A S S E S S M E N T
ACTIVE	
REWARDS GOALS	
GYM VISITS	
VITALITY FITNESS	
CLASSES	
HEART-RATE	
WORKOUTS	
PERSONALISED	
STEP GOALS	
PARKRUN	
TEAM VITALITY
SLEEP DURATION	
SLEEP	
REGULARITY	
SLEEP QUALITY
H A B I T	
F O R M A T I O N
H E A R T	
H E A L T H	H E A L T H Y	
F O O D
H E A L T H Y	
C A R E
S P E C I A L I S T	
R E F E R R A L
P A T H O L O G Y
26x
0
5
10
15
20
2024 2025 2026 2027
Employers Health plan
1.7m
3.6m
1.1m
0
20
40
60
80
100
120
2024 2025 2026 2027
Revenue ($m)	Lives (m)
>18m
HealthEquity partnership extends Vitality's
reach to 10m+ HSA account holders
Adding c11m lives through the recent
acquisition
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame

-- 54 of 62 --

55
Ping An Health
Insurance

-- 55 of 62 --

56
2022 2023 2024 2025 2026
Ping An Health Insurance
1 Costs include Vitality apportioned costs, which increased $10.8 million; 2 100% PAHI; 3 Unaudited SCR
PAHI’s operating
results pre-tax
Comprehensive
capital
PAHI licence
new business2 Lives
+31%
289%
+10%	-6%
to RMB3.3bn
RMB831m DSY’s share
SCR cover3
to 35.4m	to RMB4.5bn
DSY’s operating
result after tax
and costs1
+14%
to RMB545m
2022 2023 2024 2025 2026 2022 2023 2024 2025 2026
Jun-19	
Jun-20	
Jun-21	
Jun-22	
Jun-23	
Jun-24	
Jun-25	
Jun-26
2022 2023 2024 2025 2026
Investment income and gains
Profit before investment
income and gains
+21%
before investment
income and gains
RMB207m (+25%)
DSY share of PAHI cash dividend:
(ZAR530m)
+17%
to RMB15bn

-- 56 of 62 --

57
Broader new business mix strengthening book quality
Single product to diversified portfolio Growth in key channels
New business written premium (RMBm)
Today: Diversified products supported
by HuoLiGo ("VitalityGO")
Special disease products
Supports comprehensive needs for major diseases in
cardiovascular and cerebrovascular diseases, cancer etc.
Segment specific products
Tailored health cover for children, women, the elderly
population
Historically: One-dimensional
Managed care & health management
Covering standard and sub-standard lives. Extended
underwriting and condition management based on regular
screening, health checkup, risk assessment and stratification
eShengBao
Medical-reimbursement insurance · Flagship product
High-value products
Cater for increasing demands in insurance coverage and
more diversified healthcare services
Sui Shen Yi Online third-party
channel
Offline third-party
channel
FY25 FY26
+107%
+83%
+378%

-- 57 of 62 --

58
Strong performance in a competitive market
1 Sources: Swiss Re Institute (2025; Vitality Asia analysis. GDP: Gross Domestic Product, DRG/DIP: Diagnosis-Related Group / Diagnosis-Intervention Package (public payment reform), SHI: Social Health Insurance, CHI: Commercial Health Insurance, NFRA: National Financial Regulatory
Administration
Growth in market share Strong premium growth
0%
2%
4%
6%
8%
10%
12%
2022 2023 2024 2025 2026
PAHI market share (%) 100% PAHI licence earned premium
Macro environment1
Growth is slowing but shifting:
• GDP +4.7% in H1 2026
• Property & infrastructure investment declined
• Shift to higher-value sectors: Internet & telecoms
+19.1%; Transport equipment +13.6%; EV exports +71.2%
Healthcare focus is growing:
• 15th Five-Year Plan prioritises health quality &
outcomes
• CHI penetration up 4x in 10 years
• CHI density up 8x in 10 years
• Protection gap: USD 377bn (2024), 2x level in 2014
Regulatory reform supports expansion:
• DRG/DIP reforms support complementary cover
• SHI-CHI integration strengthening
• Key enablers: NFRA Guiding Opinions (Doc. 34) and
Commercial Innovative Drug List
Market competition is intensifying:
• CHI premium growth slowed to 8.2%; below 2016-19
CAGR of 20.5%
• Rising competitive pressure
• Increasing adverse selection risk
+9%
-
2
4
6
8
10
12
14
16
18
20
2022 2023 2024 2025 2026
Billions
10%

-- 58 of 62 --

59
UK	
Global	
Markets
Health Insurance
Vitality AI

-- 59 of 62 --

60
Summary
1
2
3
Business model
Financial framework
Business strategy
Normalised
profit growth
Cash conversion
ratio Normalised RoE	Leverage
% spend on new
Dividend cover
17%
FY26
85% 16.5%
4.5x
2%
12.8% (15.4% incl 1DP)
Super Bank strategy Vitality AI
12.5% to 17.5%
20% to 30%
average earnings growth p.a.
(FY25-FY29)
average earnings growth p.a.
(FY25-FY29)

-- 60 of 62 --

61
Presentation disclaimer
This presentation may contain forward-looking statements with respect to certain of
Discovery’s plans and its current goals and expectations relating to its future performance
and results. All forward-looking statements involve risk and uncertainty because they relate
to future events and circumstances which are beyond Discovery’s control. Accordingly,
Discovery’s actual future financial performance and results may differ. Any reference to
future financial performance has not been reviewed or reported on by the Group’s auditors.

-- 61 of 62 --

62
Audited Results
for the year ended
30 June 2026

-- 62 of 62 --